This area of the site requires the Acrobat Reader and the ability to view zipped files. Click below to download the necessary software. The StuffIt software can be used for either Windows or Macintosh.
Introduction of late INa inhibitors has extended antianginal options for clinicians.
Clinical experience to date with ranolazine, the first of this class to be approved, indicates that it has potential applications in a broad range of patients.
Resources
